Poxel Announces its Financial Calendar for 2018

Poxel Announces its Financial Calendar for 2018

Lyon, France, December 19, 2017 – POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, announces its schedule for the publication of financial information for 2018.



2017 Fourth Financial Update

January 22, 2018

2017 Full Year Statement

March 22, 2018

2018 First Quarter Financial Update

April 23, 2018

2018 Second Quarter Financial Update

July 10, 2018

2018 First Half Statement

September 19, 2018

2018 Third Quarter Financial Update

October 16, 2018

2018 Fourth Quarter Financial Update

January 22, 2019

*Subject to modification

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes. We have successfully completed our Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., EU and Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)


Poxel SA

Jonae R. Barnes
Senior Vice President, Investor Relations and Public Relation
+1 617 818 2985

Investor relations / Media - EU/US
Trophic Communications
Gretchen Schweitzer or Stephanie May
+49 89 23887734 or +49 171 855682

Investor relations / Media - France
Florent Alba/Nicolas Mérigeau
+33 1 44 71 98 55